Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli

Journal of Infection

Volumn 55, Issue 3, 2007, Pages 254-259

  Melzer, Mark ^a   Petersen, Irene ^b  

^a QUEEN S HOSPITAL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Bacteraemia; Death; ESBL producing E. coli; Mortality

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFOTAXIME; CEFTAZIDIME; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; METRONIDAZOLE; TRIMETHOPRIM;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BILIARY TRACT INFECTION; CONTROLLED STUDY; DEATH; ENZYME SYNTHESIS; ESCHERICHIA COLI; FEMALE; HUMAN; INFORMATION PROCESSING; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; OUTCOME ASSESSMENT; PATHOGENESIS; PRESCRIPTION; SINGLE DRUG DOSE; STRAIN DIFFERENCE; SURVIVAL RATE; THERAPY DELAY; TIME; TREATMENT FAILURE; URINARY TRACT INFECTION;

EID: 34547839185     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2007.04.007     Document Type: Article

References (32)

1. Mokady D., Gophna U., and Ron E.Z. Virulence factors of septicaemic E. coli strains. Int J Med Microbiol 295 6-7 (2005) 455-462
2. Gransden W.R., Eykyn S.J., Phillips I., and Rowe B. Bacteraemia due to E. coli: a study of 861 episodes. Rev Infect Dis 12 6 (1990) 1008-1018
3. Woodford N., Ward M.E., Kaufmann M.E., Turton J., Fagan J., James D., et al. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK. J Antimicrob Chemother 54 (2004) 735-743
4. Health Protection Agency. Pearson A, Livermore D, McCloskey B, Duckworth G. Investigations into multi-drug resistant ESBL-producing Escherichia coli strains causing infections in England. Available from: .
5. Health Protection Agency, Livermoore D, Pillay D, Cane P. Antimicrobial resistance. Inevitable but not unmanageable. Available from: .
6. Jacoby G.A., and Monez-Price L.S. The new beta-lactamases. N Engl J Med 352 4 (2005) 380-391
7. Health Protection Agency. Laboratory detection and reporting of bacteria with extended spectrum beta-lactamases; 2006 [National standard method QSOP 51 issue 2.]. Available from: .
8. Lautenbach E., Metlay J.P., Bilker W.B., Edelstein P.H., and Fishman N.O. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy. Clin Infect Dis 41 7 (2005) 923-929
9. Ramphal R., and Ambrose P.G. Extended-spectrum beta-lactamases and clinical outcomes: current data. Clin Infect Dis 42 (2006) S164-S172
10. Ho P.L., Chan W.M., Tsang K.W., Wong S.S., and Young K. Bacteraemia caused by Escherichia coli producing extended-spectrum beta-lactamase: a case control study of risk factors and outcomes. Scand J Infect Dis 34 8 (2002) 567-573
11. Schwaber M.J., Navon-Venezia S., Kaye K.S., Ben-Ami R., Schwartz D., and Carmeli Y. Clinical and economic impact of bacteraemia with expended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 50 4 (2006) 1257-1262
12. Zaoutis T.E., Goyal M., Chu J.H., Coffin S.E., Bell L.M., Nachamkin I., et al. Risk factors for and outcomes of bloodstream infections caused by extended-spectrum-beta-lactamase producing Escherichia coli and Klebsiella species in children. Pediatrics 115 4 (2005) 942-949
13. Kim Y.K., Pai H., Lee H.J., Park S.E., Choi E.H., Kim J., et al. Bloodstream infections by extended spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother 46 (2002) 1481-1491
14. Blomberg B., Jureen R., Manji K.P., Tamim B.S., Mwakagile D.S., Urassa W.K., et al. High rate of fatal cases of paediatric septicaemia caused by gram negative bacteraemia with extended-spectrum beta-lactamases in dar es salaam, Tanzania. J Clin Microbiol 43 2 (2005) 745-749
15. Kang C.I., Kim S.H., Pank W.B., Lee K.D., Kim H.B., Kim E.C., et al. Bloodstream infections due to extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcomes with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 48 12 (2004) 4574-4581
16. Du B., Lang Y., Liu H., Chen D., Liu D., Xu Y., et al. Extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Med 28 12 (2002) 1718-1723
17. Henshke-Bar-Meir R., Yinnon A.M., Rudensky B., Attias D., Schlesinger Y., and Raveh D. Assessment of the clinical significance of production of extended-spectrum beta-lactamases (ESBL) by Enterobacteriaceae. Infection 34 2 (2006) 66-74
18. Skippen I., Shemko M., Turton J., Kaufmann M.E., Palmer C., and Shetty N. Epidemiology of infections caused by extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella spp.: a nested case-control study from a tertiary hospital in London. J Hosp Infect 64 (2006) 115-123
19. Meton G., Zarakolu P., Cakir B., Hascelik G., and Uzun O. Clinical outcomes and therapeutic options of bloodstream infections caused by ESBL producing E. coli. Int J Antimicrob Agents 26 3 (2005) 254-257
20. Bin C., Hui W., Renyua Z., Yongzhong N., Xiuli X., Yingchun X., et al. Outcome of cephalosporin treatment of bacteraemia due to the CTX-M-type extended-spectrum beta-lactamase producing Escherichia coli. Diagn Microbiol Infect Dis 56 4 (2006) 351-357
21. Rodriguez-Bano J., Navarro M.D., Romero L., Muniain M.A., De Cueto M., Rios M.J., et al. Bacteraemia due to extended-spectrum beta-lactamase producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 43 11 (2006) 1407-1414
22. Calbo E., Romani V., Xercarins M., Gomez L., Vidal C.G., Quintana S., et al. Risk factors for community-onset urinary tract infections due to E. coli harbouring extended-spectrum beta-lactamases. J Antimicrob Chemother 57 4 (2006) 780-783
23. Babini G.S., Yuan M., Hall L.M., and Livermore D.M. Variable susceptibility to piperacillin/tazobactam amongst Klebsiella spp. with extended-spectrum beta-lactamases. J Antimicrob Chemother 51 3 (2003) 605-612
24. Pagani L., Migliavacca R., Luzzaro F., Giacobone E., Perilli M., Micheletti P., et al. Comparative activity of piperacillin/tazobactam against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae. Chemotherapy 44 6 (1998) 377-384
25. Kirkwood B.R., and Sterne J.A.C. Essential medical statistics. 2nd ed. (2003), Blackwell Publishing p. 179-180
26. Eykyn S.J., and Phillips I. Community outbreak of multiresistant invasive Escherichia coli infection. Lancet 2 8521-22 (1986) 1454
27. Phillips I., Eykyn S., King A., Gransden W.R., Rowe B., Frost J.A., et al. Epidemic multiresistant Escherichia coli infection in West Lambeth health district. Lancet 1 8593 (1988) 1038-1041
28. Branger C., Zamfir O., Geoffroy S., Laurans G., Arlet G., Thien H.V., et al. Genetic background of Escherichia coli and extended-spectrum beta-lactamase type. Emerging Infect Dis 11 1 (2005) 54-61
29. Lavigne J.P., Blanc-Potard A.B., Bourg G., Moreau J., Chanal C., Bouziges N., et al. Virulence genotype and nematode-killing properties of extra-intestinal Escherichia coli producing CTX-M beta-lactamases. Clin Microbiol Infect 12 12 (2006) 1199-1206
30. Pitout J.D., Laupland K.B., Church D.L., Menard M.L., and Johnson J.R. Virulence factors of Escherichia coli isolates that produce CTX-M-type extended-spectrum beta-lactamases. Antimicrob Agents Chemother 49 11 (2005) 4667-4670
31. Ramphal R., and Ambrose P.G. Extended-spectrum beta-lactamase and clinical outcomes: current data. Clin Infec Dis 42 (2006) S164-S172
32. Pulluku H., Tasbakan M., Sipahi O.R., Yamazhan T., Aydemir S., and Ulusoy S. Fosomycin in the treatment of extended spectrum beta-lactamase producing Escherichia coli related lower urinary tract infections. Int J Antimicrob Agents 29 1 (2007) 62-65